Meropenem Steriscience (Meropenem)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the cross‑linking of peptidoglycan strands. This action compromises the integrity of the bacterial cell wall, leading to osmotic lysis and bacterial death, and provides broad coverage against many Gram‑negative, Gram‑positive and anaerobic organisms.

The dosage of Meropenem Steriscience is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. No fixed regimen is provided here; the prescriber will set the appropriate dose and infusion schedule.

Safety data for meropenem during pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should evaluate each case individually and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain logistics if needed) and assists with import documentation.

Meropenem offers a broad spectrum of activity similar to other carbapenems such as imipenem‑cilastatin and ertapenem, but it has enhanced stability against many β‑lactamases and a lower propensity for inducing seizures. Compared with non‑carbapenem β‑lactams, it provides superior coverage of resistant Gram‑negative organisms, making it a preferred option for high‑risk hospital infections.

Meropenem Steriscience must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be allowed to reach room temperature if required, and any unused portion should be discarded according to local regulations.

The product is supplied as an injectable solution for intravenous infusion. It is typically administered over a 15‑ to 30‑minute infusion period, but the exact rate and duration are determined by the prescribing clinician based on infection severity, patient condition, and renal function.

Serious adverse events include seizures (particularly in patients with renal impairment or pre‑existing CNS disorders), Clostridioides difficile‑associated colitis, severe hypersensitivity reactions such as anaphylaxis, and acute renal dysfunction. Prompt recognition and discontinuation of therapy are essential if any of these events occur.

Meropenem is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving interacting medications that could increase toxicity.